Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.

Nishie W.

Open source

DOI
10.1080/25785826.2019.1619233
Published
2019-03-01
Container
Immunol Med
Publisher
Not recorded
Open access
no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/25785826.2019.1619233,
  title = {Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.},
  author = {Nishie W.},
  year = {2019},
  journal = {Immunol Med},
  doi = {10.1080/25785826.2019.1619233},
  url = {https://doi.org/10.1080/25785826.2019.1619233}
}

RIS

TY  - JOUR
TI  - Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
AU  - Nishie W.
PY  - 2019
JO  - Immunol Med
DO  - 10.1080/25785826.2019.1619233
UR  - https://doi.org/10.1080/25785826.2019.1619233
ER  - 

APA

W., N. (2019). Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.. Immunol Med. https://doi.org/10.1080/25785826.2019.1619233

Source records